- RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
For: Colorectal NeoplasmsUnited States · Belgium · Brazil - Active not recruitingPHASE1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is for adults with head and neck cancer that has spread or returned. It tests if combining new medicines like BI 770371, pembrolizumab, and cetuximab can shrink tumors better than pembrolizumab alone. It aims to see if these combinations help the immune system fight cancer.
For: Head and Neck Squamous Cell CarcinomaUnited States · Australia · Brazil - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - RecruitingPHASE1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This study looks at new treatments for bowel cancer that has spread. We want to see if these targeted medicines or immunotherapy are safe and work well for people whose cancer has specific genetic features, which we call biomarkers.
For: Metastatic Colorectal CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
This study is for people with advanced bowel cancer where previous chemotherapy hasn't worked. It compares a new drug called amivantamab, plus standard FOLFIRI chemotherapy, against other established treatments (cetuximab or bevacizumab) with FOLFIRI, to see which works best.
For: Colorectal NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
This study, KRYSTAL-10, is for people with advanced bowel cancer that has a specific genetic change (KRAS G12C). It compares a combination of new drugs, MRTX849 and cetuximab, against standard chemotherapy to see which works better for those who have already had initial treatment.
For: Advanced Colorectal Cancer · Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
This study is looking at a new combination of medicines, ficlatuzumab and cetuximab, for people with head and neck cancer that has come back or spread, and tested negative for HPV. It aims to see if this new combination works better than cetuximab alone.
For: Metastatic Head-and-neck Squamous-cell Carcinoma · Recurrent Head and Neck Squamous Cell CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
This study looks at a new drug, Monalizumab, combined with Cetuximab, for people with head and neck cancer that has come back or spread. It compares this combination to Cetuximab with a dummy drug (placebo) to see if it's safe and effective.
For: Squamous Cell Carcinoma of the Head and NeckUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
For: Colon Adenocarcinoma · Rectal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE4
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
This study, called FLOTILLA, offers continued access to cancer medicines encorafenib and binimetinib for people who have already taken part in earlier clinical trials. It's for those still benefiting from the treatment.
For: Solid TumorsUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
For: Non-small Cell Lung Cancer · Histiocytic Neoplasm · HistiocytosisUnited States · Australia · China - RecruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
For: Solid Tumors · Advanced Solid Tumors · Metastatic Solid TumorsUnited States · China · Denmark - RecruitingPHASE1
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
This study is looking into a new treatment, MK-4716, for certain advanced cancers. We want to see how safe it is and how well people tolerate it, either alone or with other medicines. The goal is to find better ways to treat these cancers.
For: Malignant NeoplasmUnited States · Australia · Canada - RecruitingPHASE1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
This study is testing a new medicine, PF-07799933, for advanced cancers with a specific gene change (BRAF alterations). It aims to see how safe and effective it is, sometimes combined with other medicines, for people when usual treatments haven't worked.
For: Melanoma · Non-Small-Cell Lung Cancer · Thyroid CancerUnited States · Canada · Israel - Active not recruitingPHASE2
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at combining three medicines for advanced bowel cancer that has spread. It compares a new combination therapy (encorafenib, cetuximab, and pembrolizumab) with pembrolizumab alone for patients who haven't had treatment yet and have specific gene changes.
For: Metastatic Colorectal CancerUnited States · Australia · Belgium - Recruiting
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
This study looks at how a specific treatment (encorafenib and cetuximab) works in real life for advanced bowel cancer with a particular gene change (BRAFV600E mutation). It also checks quality of life, safety, and how well it's tolerated in everyday use.
For: Metastatic Colorectal CarcinomaAustria · Germany - RecruitingPHASE1
A Study of ASP3082 in Adults With Advanced Solid Tumors
This study looks at a new drug, ASP3082, for adults with advanced solid cancers that have a specific genetic change called KRAS G12D. It checks how safe the drug is and what dose works best, sometimes with another drug called cetuximab.
For: Solid TumorUnited States · China · France - Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
For: Non-Small Cell Lung Cancer · Colorectal Cancer · Advanced Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This study is looking into a new treatment, BMS-986488, for advanced cancers. Researchers want to see if it's safe, tolerable, and effective, either on its own or with other medicines, for people whose cancer has spread or can't be removed with surgery.
For: Advanced Malignant TumorsUnited States · Australia · Canada - Active not recruitingPHASE3
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
This study looks at whether adding a drug called cetuximab to standard radiation therapy helps patients with head and neck cancer after surgery. We want to see if this combination improves treatment success and helps people live longer with fewer side effects.
For: Head and Neck CancerUnited States · Canada · China - RecruitingPHASE1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
This study is testing a new drug called Calderasib, alone or with other treatments, for advanced cancers with a specific gene change (KRAS G12C). It's looking at how safe and effective these treatments are.
For: Advanced Solid TumorsUnited States · Argentina · Australia - RecruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This study is looking at a new treatment called INCB161734 for advanced cancers with a specific genetic change (KRAS G12D mutation). Researchers want to see if it's safe and how well it works, either alone or with other cancer drugs.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
This study is looking into a new medicine, calderasib, to treat certain advanced cancers. Researchers want to see if it can shrink these cancers, either alone or with another medicine called cetuximab, in people whose cancers have a specific genetic change (KRAS G12C mutation).
For: Neoplasm MalignantUnited States · Australia · Canada - Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - AuthorisedTherapeutic confirmatory (Phase III)
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation
This study is looking at a new way to help surgeons remove all cancer in people with mouth cancer. It uses a special dye (Cetuximab) and light to see if any cancer cells are left behind during surgery, aiming to improve treatment.
For: oral squamous cell carcinomaNetherlands - Active not recruitingPHASE1
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
This study looks at new ways to treat head and neck cancer. It combines different medicines that help your immune system fight cancer and stop tumours from growing. It's for people whose previous treatments weren't successful or who don't have standard options.
For: Head and Neck Squamous Cell Carcinoma (HNSCC)United States · France · Japan - RecruitingPHASE3
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
This study looks at a new treatment called JNJ-90301900 (NBTXR3) combined with standard radiation therapy, sometimes with cetuximab, for older patients with advanced head and neck cancer who can't have platinum chemotherapy.
For: Carcinoma, Squamous CellUnited States · Austria · Belgium